Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

| Name of entity        |  |  |  |  |  |
|-----------------------|--|--|--|--|--|
| WOLF MINERALS LIMITED |  |  |  |  |  |

ABN

11 121 831 472

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- +Class of +securities issued or to be issued
- a) Fully Paid Ordinary Shares
- b) Performance Rights
- Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- a) 538,039 Fully Paid Ordinary Shares
- b) 53,363 Performance Rights

<sup>+</sup> See chapter 19 for defined terms.

**Principal** terms of the 3 +securities (e.g. if options, exercise price and expiry date; if paid \*securities, amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

#### **Fully Paid Ordinary Shares**

a) 538,039 ordinary shares issued to an employee upon the exercise of vested performance rights issued in accordance with the Wolf Minerals Limited Performance Rights Plan, as approved by shareholders on 21 November 2014. One Performance Right is converted into one fully paid ordinary share in the Company for nil cash consideration.

#### **Performance Rights**

- b) The performance rights are issued in accordance with the Wolf Minerals Limited Performance Rights Plan, as re-adopted by shareholders on 21 November 2014. The vesting date is 30 June 2019. Upon vesting, one performance right is converted into one fully paid ordinary share in the Company for nil cash consideration. Vesting is subject to the following conditions:
  - (i) 50% of performance rights will vest based on the Company's relative share price performance versus the AIM Basic Resources Index in accordance with a defined scale; and
  - (ii) 50% of performance rights will vest based upon the Company's Total Shareholder Return (TSR) performance as measured from 1 July 2014 to the vesting date of 30 June 2019.

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

4 Do the \*securities rank equally in all respects from the \*issue date with an existing \*class of quoted \*securities?

If the additional \*securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

#### **Fully Paid Ordinary Shares**

 a) Yes - equally in all respects with quoted securities WLF Fully Paid Ordinary Shares

#### **Performance Rights**

b) No (not until vesting). Prior to vesting the performance rights do not carry a right to vote, receive dividends or generally participate in other corporate actions.

However ordinary shares allocated upon vesting of the performance rights will rank equally with all existing fully paid ordinary shares on issue.

#### 5 Issue price or consideration

#### **Fully Paid Ordinary Shares**

a) Nil

#### **Performance Rights**

- b) Nil
- 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)
- The exercise of vested performance rights issued in accordance with the Wolf Minerals Limited Performance Rights Plan, as approved shareholders on 21 November 2014. One Performance Right is converted into one fully paid ordinary share in the Company for nil cash consideration.
- b) The performance rights have been issued under the Wolf Minerals Limited Performance Rights Plan to provide an appropriate remuneration strategy and incentive for senior executives to achieve the prescribed performance milestones set by the Board.

<sup>+</sup> See chapter 19 for defined terms.

| 6a | Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  | Yes  |
|----|--|--|
|    | If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i   |  |
| 6b | The date the security holder resolution under rule 7.1A was passed   | 16 November 2015                                     |
| 6c | Number of *securities issued without security holder approval under rule 7.1   | Nil  |
| 6d | Number of *securities issued with security holder approval under rule 7.1A   | Nil  |
| 6e | Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)  | Nil  |
|    |  |  |
| 6f | Number of *securities issued under an exception in rule 7.2  | 538,039 Ordinary Shares<br>53,363 Performance Rights |
| 6g | If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation. | N/A  |
| 6h | If *securities were issued under<br>rule 7.1A for non-cash<br>consideration, state date on<br>which valuation of<br>consideration was released to<br>ASX Market Announcements                            | N/A  |
| 6i | Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements   | 270,856,437  |

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

| 7    | <sup>+</sup> Issue dates  | 29 July 2016  |        |   |
|------|---|---------------|--------|---|
|      | Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. |               |        |   |
|      | Cross reference: item 33 of Appendix 3B.  |               |        |   |
|      |   |               |        |   |
|      |   | Number        |        | +Class                                      |
| 8    | Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)   | 1,083,425,747 |        | Fully Paid Ordinary<br>Shares               |
|      |   | N. 1          | + 61   |   |
|      | Number and +class of all  | Number        | +Class |   |
| 9    | Number and *class of all *securities not quoted on ASX ( <i>including</i> the *securities in section 2 if applicable)   | 898,150       |        | mance rights with a g date of 30 June 2018. |
|      |   | 1,355,214     |        | mance rights with a g date of 30 June 2019. |
|      |   | 1,744,644     |        | mance rights with a g date of 30 June 2020. |
|      |   | 256,945       |        | mance rights with an of 22 December 2020.   |
| 10   | Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)  | n/a           |        |   |
| Part | 2 - Pro rata issue  |               |        |   |
| 11   | Is security holder approval required?   |               |        |   |
| 12   | Is the issue renounceable or non-renounceable?  |               |        |   |
|      | <b>D</b>  |               |        |   |
| 13   | Ratio in which the *securities will be offered  |               |        |   |
| 14   | *Class of *securities to which the offer relates  |               |        |   |
|      |   |               |        |   |

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

| 15 | *Record date to determine entitlements   |
|----|--|
| 16 | Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?   |
| 17 | Policy for deciding entitlements in relation to fractions  |
| 18 | Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7. |
| 19 | Closing date for receipt of acceptances or renunciations   |
| 20 | Names of any underwriters  |
| 21 | Amount of any underwriting fee or commission   |
| 22 | Names of any brokers to the issue  |
| 23 | Fee or commission payable to the broker to the issue   |
| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders   |
| 25 | If the issue is contingent on security holders' approval, the date of the meeting  |
| 26 | Date entitlement and acceptance form and offer documents will be sent to persons entitled  |

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

| 27  | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders   |  |
|-----|---|--|
| 28  | Date rights trading will begin (if applicable)  |  |
| 29  | Date rights trading will end (if applicable)  |  |
| 30  | How do security holders sell their entitlements <i>in full</i> through a broker?  |  |
| 31  | How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?   |  |
| 32  | How do security holders dispose of their entitlements (except by sale through a broker)?  |  |
| 33  | <sup>+</sup> Issue date   |  |
|     | Type of *securities (tick one)  *Securities described in Part   |  |
| (b) | All other *securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities |  |
|     | ies that have ticked box 3  |  |

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

| Tick to<br>łocum | o indicate you are providing the information ents  | on or  |
|------------------|--|--|
| 35               |  | securities, the names of the 20 largest holders of the number and percentage of additional <sup>+</sup> securities |
| 36               |  | securities, a distribution schedule of the additional mber of holders in the categories                            |
| 37               | A copy of any trust deed for t   | the additional *securities   |
| Enti             | ties that have ticked box 3  | 4(b)   |
| 38               | Number of *securities for which *quotation is sought   |  |
| 39               | <sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought  |  |
| 40               | Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  |  |
|                  | If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment |  |

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

| 41 | Reason for request for quotation now  |        |        |
|----|---|--------|--------|
|    | Example: In the case of restricted securities, end of restriction period                      |        |        |
|    | (if issued upon conversion of<br>another *security, clearly identify<br>that other *security) |        |        |
|    |   | Number | +Class |
| 42 | Number and +class of all +securities quoted on ASX (including the +securities in clause 38)   |        |        |

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 
  +securities to be quoted under section 1019B of the Corporations Act at 
  the time that we request that the +securities be quoted.

<sup>+</sup> See chapter 19 for defined terms.

- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Pauline Carr Date: 29 July 2016

Joint Company Secretary

== == == ==

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

| Rule 7.1 – Issues exceeding 15% of capital  |               |  |  |  |
|---|---------------|--|--|--|
| Step 1: Calculate "A", the base figure from which the placement capacity is calculated  |               |  |  |  |
| Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue  | 809,422,200   |  |  |  |
| Add the following:  |               |  |  |  |
| Number of fully paid *ordinary securities issued in that 12 month period under an exception in rule 7.2   | 1,968,727     |  |  |  |
| Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval  | 272,034,820   |  |  |  |
| Number of partly paid <sup>+</sup> ordinary<br>securities that became fully paid in that<br>12 month period   | Nil           |  |  |  |
| <ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> |               |  |  |  |
| <b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period   | Nil           |  |  |  |
| "A"   | 1,083,425,747 |  |  |  |

<sup>+</sup> See chapter 19 for defined terms.

| Step 2: Calculate 15% of "A"  |   |
|---|---|
| "B"   | 0.15  |
|   | [Note: this value cannot be changed]                          |
| Multiply "A" by 0.15  | 162,513,862   |
| Step 3: Calculate "C", the amount of that has already been used   | of placement capacity under rule 7.                           |
| Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:  | Nil   |
| Under an exception in rule 7.2  |   |
| Under rule 7.1A   |   |
| <ul> <li>With security holder approval under rule<br/>7.1 or rule 7.4</li> </ul>  |   |
| <ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> |   |
| "C"   | Nil   |
| Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1   | B"] to calculate remaining                                    |
| "A" x 0.15  | 162,513,862   |
| Note: number must be same as shown in Step 2  |   |
| Subtract "C"  | Nil   |
| Note: number must be same as shown in<br>Step 3   |   |
| <b>Total</b> ["A" x 0.15] – "C"   | 162,513,862   |
|   | Note: this is the remaining placement capacity under rule 7.1 |

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

| Rule 7.1A – Additional placement capacity for eligible entities   |                                    |  |  |
|---|------------------------------------|--|--|
| Step 1: Calculate "A", the base figure from which the placement capacity is calculated  |                                    |  |  |
| "A"   | 1,083,425,747                      |  |  |
| Note: number must be same as shown in Step 1 of Part 1  |                                    |  |  |
| Step 2: Calculate 10% of "A"  |                                    |  |  |
| "D"   | 0.10                               |  |  |
|   | Note: this value cannot be changed |  |  |
| Multiply "A" by 0.10  | 108,342,575                        |  |  |
| Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used  |                                    |  |  |
| <ul> <li>Insert number of †equity securities issued or agreed to be issued in that 12 month period under rule 7.1A</li> <li>Notes:         <ul> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul> | Nil                                |  |  |
| "E"   | Nil                                |  |  |

<sup>+</sup> See chapter 19 for defined terms.

| Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A |  |  |
|---|--|--|
| "A" x 0.10  | 108,342,575  |  |
| Note: number must be same as shown in Step 2  |  |  |
| Subtract "E"  | Nil  |  |
| Note: number must be same as shown in Step 3  |  |  |
| <b>Total</b> ["A" x 0.10] – "E"   | 108,342,575  |  |
|   | Note: this is the remaining placement capacity under rule 7.1A |  |

Appendix 3B Page 14 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.